Abselion

United Kingdom - Cambridge, England

• 10/12/2024
• Series A
• $8,412,690

Our mission at Abselion is to simplify protein quantification for the scientists making crucial decisions to accelerate the development of biotherapeutics. Our tools help researchers to develop the medicine of the future and to find the best ways to produce new biomolecules.

We focus on convenient tools with high degree of automation and low hands-on time to accelerate access to actionable data. Our award-winning Amperia system, built on proprietary Redox Electrochemical Detection (RED) technology, brings a new approach to biologics and viral-vector quantification for confident and cost-effective automated, at-line titre measurement, at any bench or bioreactor. By enabling agile and straightforward access to titre data, we empower scientists to focus on the decisions that can drive bioprocess optimisation and innovation.

We are a dynamic, interdisciplinary team working at the intersection of biology, nanotechnology and data science. We value a flat hierarchy, where everyone is encouraged to share their ideas and to follow their passion.

Related People

Ruizhi WangFounder

United States - Greater Cambridge Area

I am a passionate scientist, engineer, and entrepreneur in the field of protein analytics and nanotechnology. I founded and lead Abselion, a company that creates tools that simplify protein analytics and enables at-line process monitoring in bioprocessing. Our solutions help scientists to find the best ways to produce novel biomolecules, and to assure that medicine is always safe and efficacious.

At Abselion, I oversee the strategic direction, product development, and business operations of the company. I am proud of the dynamic, interdisciplinary team of experts in biology, nanotechnology, and data science. We value a flat hierarchy, where everyone is encouraged to share their ideas and to follow their passion.

LinkedIn https://www.linkedin.com/in/ruizhi-wang-9b839796/